-
Statistical Guidelines for Clinical Research of Rare Disease Drugs (Draft for Solicitation of Comments) released
Time of Update: 2021-12-06
On November 18th, CDE drafted the "Guiding Principles for Clinical Research of Rare Disease Drugs (Draft for Comment)", which is now open for comment .
“Guidelines for Statistics of Clinical Research on Rare Disease Drugs (Draft for Comment)” feedback form for soliciting opinions
-
New type of decoction pieces or a big outbreak, the equipment industry will have a lot to do
Time of Update: 2021-10-10
The broken-wall decoction pieces break the plant cell wall through modern ultra-fine pulverization technology, and release the effective ingredients of traditional Chinese medicine so that the ingredients can be better absorbed by the human body.
-
Has a good opportunity for big pig farmers to enter the market for half a year after the hog futures is listed
Time of Update: 2021-08-03
DCE told a reporter from China Business Daily that the price of live pigs has fallen sharply since June, and the industry and companies have a better understanding of the role of the futures market.
-
Fuan Pharmaceutical's Rocuronium Bromide Injection passed the consistency evaluation of generic drugs
Time of Update: 2021-07-07
, a wholly-owned subsidiary of Fuan Pharmaceutical Group, had recently received a supplementary drug application approval notice issued by the National Medical Products Administration.
Its product rocuronium Ammonium injection passed the quality and efficacy consistency evaluation of generic drugs .
-
No need to change pregnancy risk data label GlaxoSmithKline wins Zofran safety lawsuit
Time of Update: 2021-06-11
Therefore, Judge Saylor believes that the FDA refused to add pregnancy warning labels in accordance with the obligations imposed on it by federal law, and the US federal law takes precedence over the plaintiff’s claim in state law that no safety warning has been issued.
-
How does the number and scale of public hospitals develop? The Health and Wellness Commission replied
Time of Update: 2021-03-24
According to the "Reply", the National Health Commission is studying and revising the national medical and health service system plan, scientifically determining the number, scale and layout of public hospitals and social hospitals, rationally adjusting the bed allocation standards of public hospitals, and supporting some powerful public hospitals On the basis of controlling the size of the single unit, appropriate construction and development of multiple hospitals, and rapid conversion of functions when a major epidemic occurs.
-
Antibiotic injection growth slides Carbon penicillin down 9% YoY
Time of Update: 2021-02-16
According to Minenet data, in the first three quarters of 2017, the amount of carbon penicillin antimicrobial drugs used in public hospitals in key cities in China was RMB1,666 million, resulting in a forecast of RMB2.332 billion for the whole of 2017, an increase of 4.80 percent year-on-year and a decrease of 9 percentage points year-on-year.
-
Cordis, the pharmaceutical giant, wants to add to the Chinese market
Time of Update: 2021-02-13
"As the drug stent market matures rapidly, (Johnson and Johnson) has found the ability to help more patients in other areas of cardiovascular disease while promoting the company's growth." four-and-a-half years, the new owner of Cordis, which is separated from the Johnson and Johnson system, is Kantle, the medical-business giant.
-
How to rob the drug king Shumeile 10 billion self-free market
Time of Update: 2021-01-20
The company continues to sell strong TNF alpha as the most successful target for the development of autoimmune diseases, and before TNF alpha inhibitors emerged, patients including rheumatoid arthritis, psoriasis and other patients did not have many drug options, poor quality of life, the current TNFa inhibitors are the big three are AbbVie, Pfizer and Johnson and Johnson, creating a $10 billion autoimmune disease market.
-
The GALACTIC trial failed and the new drug project to cut heart failure was returned to Cytokinetics
Time of Update: 2021-01-07
The trial eventually reached its main endpoint, and after 21.8 months of median follow-up, omecamtiv mecarbil statistically reduced the risk of the main complex endpoints of cardiovascular death or heart failure events (HR-0.92; 95%CI:0.86,0.99; p-0.025) compared to placebo.
-
In the next five to ten years, the pharmaceutical industry is expected to appear 10 times or even 50 times the bull stock
Time of Update: 2020-11-11
From the point of view of the drug use structure, in recent years, drug reviews have been increasing rapidly, coupled with the promotion of consistent evaluation and the publication of the list of complementary medications, some of the drugs that were privileged in the past are no longer covered by health insurance or have reduced reimbursement rates.
-
As policies drive a surge in overlay demand, opportunities in the pharmaceutical industry will continue to emerge
Time of Update: 2020-11-10
industry pointed out that from 2019, the pharmaceutical industry's policy dividend continues to release, the pharmaceutical industry sub-circuit contains raw materials, innovative drugs, medical services, health care and other 7 fine molecular industries, some sub-circuits may be available in the future opportunities, the relevant advantages of enterprises are expected to taste the sweetness.
-
52 drugs are out of supply nationwide
Time of Update: 2020-11-01
As early as July 2, the Inner Mongolia Pharmaceutical Harvesting Center issued a notice that: from March 1 to June 30, 2020, due to rising raw materials, production line transformation, drug approval was withdrawn and other reasons led to the cessation of production of many drugs, 20 pharmaceutical companies to Inner Mongolia to apply for the disqualification of 40 drugs, and submitted a unified national non-supply commitment letter.
-
183 drug reviews cost up to tens of millions of dollars to develop
Time of Update: 2020-10-29
At the same time, after the third batch of national drug collection of the winning results, generic drug consistent evaluation of the corresponding research and development costs have become the focus of public opinion in the industry, exploring the industry, enterprises are looking forward to, willing to support the policy of support, supervision means, is an important issue that can not be avoided at present.
-
With 1.9 billion injections, this Jiangsu pharmaceutical company will be the first to be evaluated
Time of Update: 2020-10-10
/long-chain fat emulsion is a fast and short-acting intravenous anesthetic with terminal sales of more than 1.9 billion yuan in public medical institutions in China in 2019.
